Laddar populära aktier...
Redeye provides a more in-depth review of Episurf Medical’s Q3 report.
Redeye provides a short comment on Episurf's announcement about the revised estimated timeline for FDA clearance of its 510(k) application f...
Redeye provides a more in-depth review of Episurf Medical’s Q2 report.
Redeye comments on the outcome of Episurf Medical’s rights issue of units that secured the company SEK90m before issue costs.
We note another quarter in which the operations have not yet translated into meaningful sales.
Redeye comments on the announcement of a SEK120m rights issue of units.
Redeye reviews its financial estimates on all time horizons following Episurf Medical's most recent strategy update and its progression in t...
Redeye comments on Episurf Medical’s Q4 report and notes important key activities carried out in the quarter.
Redeye provides a more indepth take on Episurf Medical’s Q3 report.
Redeye views the 510(k) submission for the MTP joint implant product as a positive step towards its broadening portfolio within the US marke...
Redeye has a neutral stance on Episurf Medical’s Q2 report as sales have yet to take off.
Episurf Medical’s Q1 sales were broadly in line with our estimate, while operating expenses were slightly higher than we expected.
Redeye returns with a more detailed take on Episurf Medicals’ Q1 report, and we make some changes to our FY 2023 estimates.
Q4 earnings were below our forecast, but there were clear positives in the report including a growing customer base and the first distributi...
Redeye notes a continuous customer base growth (+72%), and we are encouraged by the company’s FDA approval for its Episealer Patellofemoral ...
Episurf recently announced that it has received its first product clearance for use on the US market.
Redeye is encouraged by the FDA approval for Episurf Medical’s patellofemoral system product and argues that 2023 will be an exciting year t...
Episurf Medical hosted a CMD on 16 November at which it discussed the state of the company and its long-term plans.
Episurf Medical held a capital markets day on the 16th of November.
Redeye reiterates its fair value range for Episurf Medical following the Q3 report.
Redeye is encouraged to see Episurf delivering on its activities for inclusion in UK NICE guidelines.
Redeye comments on Episurf’s Q2 report and notes a quarter in line with our expectations both financially and in terms of activities.
Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes several crucial activities carried out that ...
We expected soft Q1 sales due to the Omicron wave in early Q1.
Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and that its potential US market entry by H...
Q4 was clearly hit by Covid-19, but we expect things to improve over the coming quarters (although Q1 might still see some negative impact).
Redeye provides its initial comments on the report ahead of a more detailed update discussing the case as we advance into 2022.
The company reported its Q3 earnings (loss) on 29 October, but the key information was already known (released with the capital raise in mid...
Episurf Medical last night reported preliminary Q3 results as well as a capital raise of cSEK159m, which should secure its financial positio...
Redeye embraces the ever-growing clinical evidence for Episurf Medical, as yet another study is set to be published in a peer-reviewed scien...
Redeye welcomes the additional clinical data to Episurf’s impressive and growing library of publications.
The company announced on 2 September that the 5–7-year follow-up data for the first trial with the Episealer system has been accepted for pu...
The Q2 report was essentially in line with our expectations.
Redeye notes another interim report with steps taken in the right direction.
